NCT04784715: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with spinal cord compression or clinically active central nervous system metastases; Patients with prior treatment in a previous trastuzumab deruxtecan study; Patients with prior chemotherapy or HER2-targeted therapy (e.g. Herceptin/trastuzumab, Nerlynx/neratinib, etc.) for advanced or metastatic breast cancer; Patients with more than 1 previous line of endocrine therapy in the metastatic setting

Comments are closed.

Up ↑